查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386934

全球静脉注射免疫球蛋白市场：趋势、预测与竞争分析（-2030）

Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

静脉注射免疫球蛋白的趋势和预测

预计2030年，全球静脉注射注射免疫球蛋白市场规模将达到约246亿美元，2024年至2030年年复合成长率为7.6%。这个市场的主要驱动力是老年人口的增加、血友病患者数量的增加、免疫球蛋白生产的新技术以及精製方法的改进（提高血浆产量）。全球静脉注射免疫球蛋白市场的未来充满希望，医院、居家医疗和专科诊所市场充满机会。

静脉注射免疫球蛋白市场洞察

Lucintel 预测，由于人们越来越关注基于个别患者的诊断和治疗，以及大多数患者无法适应自我给药，因此免疫力缺乏疾病将变得更加普遍。在预测期内，免疫缺陷疾病将继续成为最大的细分市场。

医院将继续成为该市场的最大细分市场。这是因为原发性免疫力缺乏症、C型肝炎等疾病的盛行率不断上升，导致住院患者人数迅速增加，全球医院药局的需求也随之增加。

由于临床医生对治疗的需求不断增加、医疗保健支出不断增加以及大公司的存在，北美将继续成为最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球静脉注射免疫球蛋白市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势与预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球静脉注射免疫球蛋白市场趋势（2018-2023）与预测（2024-2030）
  • 全球静脉注射免疫球蛋白市场：依应用分类
    • Hypogammaglobulinemia
    • CIPD
    • Immunodeficiency Diseases
    • Congenital AIDS
    • Chronic Lymphocytic Leukemia
    • Myasthenia Gravis
    • Multifocal Motor Neuropathy
    • Kawasaki Disease
    • Guillain-Barre Syndrome
  • 全球静脉注射免疫球蛋白市场：依配销通路
    • 静脉
    • 皮下的
  • 全球静脉注射免疫球蛋白市场：依最终用途分类
    • 医院
    • 居家医疗
    • 专科诊所
    • 其他的
  • 全球静脉注射免疫球蛋白市场：依型态
    • 液体
    • 冷冻干燥

第4章市场趋势与预测分析：按地区（2018-2030）

  • 全球静脉注射免疫球蛋白市场：按地区
  • 北美静脉注射免疫球蛋白市场
  • 欧洲静脉注射免疫球蛋白市场
  • 亚太静脉静脉注射免疫球蛋白市场
  • 其他地区静脉注射免疫球蛋白市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球静脉注射免疫球蛋白市场成长机会（按应用）
    • 按配销通路的全球静脉注射免疫球蛋白市场成长机会
    • 按最终用途分類的全球静脉注射免疫球蛋白市场成长机会
    • 全球静脉注射免疫球蛋白市场成长机会（按型态）
    • 全球静脉注射免疫球蛋白市场成长机会（按地区）
  • 全球静脉注射免疫球蛋白市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球静脉注射免疫球蛋白市场的产能
    • 全球静脉注射免疫球蛋白市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Baxter
  • Bayer
  • Merck
  • Biotest
  • Top Bio
  • CSL
  • Octapharma
  • Grifols
  • Kedrion
  • Takeda Pharmaceuical
简介目录

Intravenous Immunoglobulin Trends and Forecast

The future of the global intravenous immunoglobulin market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global intravenous immunoglobulin market is expected to reach an estimated $24.6 billion by 2030 with a CAGR of 7.6% from 2024 to 2030. The major drivers for this market are increasing geriatric population, rising number of hemophiliacs, and new technologies related to the generation of immunoglobulin, and improved purification methods (with improved plasma yield).

A more than 150-page report is developed to help in your business decisions.

Intravenous Immunoglobulin by Segment

The study includes a forecast for the global intravenous immunoglobulin by application, distribution channel, end use, form, and region.

Intravenous Immunoglobulin Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hypogammaglobulinemia
  • CIPD
  • Immunodeficiency Diseases
  • Congenital AIDs
  • Chronic Lymphocytic Leukemia
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Kawasaki Disease
  • Guillain-Barre Syndrome
  • Others

Intravenous Immunoglobulin Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Intravenous
  • Subcutaneous

Intravenous Immunoglobulin Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Intravenous Immunoglobulin Market by Form [Shipment Analysis by Value from 2018 to 2030]:

  • Liquid
  • Lyophilized

Intravenous Immunoglobulin Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Intravenous Immunoglobulin Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies intravenous immunoglobulin companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the intravenous immunoglobulin companies profiled in this report include-

  • Baxter
  • Bayer
  • Merck
  • Biotest
  • Top Bio
  • CSL
  • Octapharma
  • Grifols
  • Kedrion
  • Takeda Pharmaceuical

Intravenous Immunoglobulin Market Insights

Lucintel forecasts that immunodeficiency diseases will remain the largest segment over the forecast period due to increasing focus towards the diagnosis and treatment based on individual patient and training of patients as most of the patients are not adaptable towards self administration.

Within this market, hospital will remain the largest segment due to the increasing prevalence of primary immunodeficiency and hepatitis c, as well as other diseases, has led to surge in hospitalizations around the world, thus increasing the demand for hospital pharmacies.

North America will remain the largest region due to growing demand of therapies among clinicians, rising healthcare expenditure, and presence of major players in the region.

Features of the Global Intravenous Immunoglobulin Market

Market Size Estimates: Intravenous immunoglobulin market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Intravenous immunoglobulin market size by various segments, such as by application, distribution channel, end use, form, and region in terms of value ($B).

Regional Analysis: Intravenous immunoglobulin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different applications, distribution channels, end uses, forms, and regions for the intravenous immunoglobulin market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the intravenous immunoglobulin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the intravenous immunoglobulin market size?

Answer: The global intravenous immunoglobulin market is expected to reach an estimated $24.6 billion by 2030.

Q.2 What is the growth forecast for intravenous immunoglobulin market?

Answer: The global intravenous immunoglobulin market is expected to grow with a CAGR of 7.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the intravenous immunoglobulin market?

Answer: The major drivers for this market are increasing geriatric population, rising number of hemophiliacs, and new technologies related to the generation of immunoglobulin, and improved purification methods (with improved plasma yield).

Q4. What are the major segments for intravenous immunoglobulin market?

Answer: The future of the global intravenous immunoglobulin market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q5. Who are the key intravenous immunoglobulin market companies?

Answer: Some of the key intravenous immunoglobulin companies are as follows:

  • Baxter
  • Bayer
  • Merck
  • Biotest
  • Top Bio
  • CSL
  • Octapharma
  • Grifols
  • Kedrion
  • Takeda Pharmaceuical

Q6. Which intravenous immunoglobulin market segment will be the largest in future?

Answer: Lucintel forecasts that immunodeficiency diseases will remain the largest segment over the forecast period due to increasing focus towards the diagnosis and treatment based on individual patient and training of patients as most of the patients are not adaptable towards self administration.

Q7. In intravenous immunoglobulin market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to growing demand of therapies among clinicians, rising healthcare expenditure, and presence of major players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the intravenous immunoglobulin market by application (hypogammaglobulinemia, CIPD, immunodeficiency diseases, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, kawasaki disease, guillain-barre syndrome, and others), distribution channel (intravenous and subcutaneous), end use (hospitals, homecare, specialty clinics, and others), form (liquid and lyophilized), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Intravenous Immunoglobulin Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Intravenous Immunoglobulin Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Intravenous Immunoglobulin Market by Application
    • 3.3.1: Hypogammaglobulinemia
    • 3.3.2: CIPD
    • 3.3.3: Immunodeficiency Diseases
    • 3.3.4: Congenital AIDS
    • 3.3.5: Chronic Lymphocytic Leukemia
    • 3.3.6: Myasthenia Gravis
    • 3.3.7: Multifocal Motor Neuropathy
    • 3.3.8: Kawasaki Disease
    • 3.3.9: Guillain-Barre Syndrome
  • 3.4: Global Intravenous Immunoglobulin Market by Distribution Channel
    • 3.4.1: Intravenous
    • 3.4.2: Subcutaneous
  • 3.5: Global Intravenous Immunoglobulin Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Homecare
    • 3.5.3: Specialty Clinics
    • 3.5.4: Others
  • 3.6: Global Intravenous Immunoglobulin Market by Form
    • 3.6.1: Liquid
    • 3.6.2: Lyophilized

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Intravenous Immunoglobulin Market by Region
  • 4.2: North American Intravenous Immunoglobulin Market
    • 4.2.2: North American Intravenous Immunoglobulin Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.3: European Intravenous Immunoglobulin Market
    • 4.3.1: European Intravenous Immunoglobulin Market by Application: Hypogammaglobulinemia, CIPD, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, and Others
    • 4.3.2: European Intravenous Immunoglobulin Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.4: APAC Intravenous Immunoglobulin Market
    • 4.4.1: APAC Intravenous Immunoglobulin Market by Application: Hypogammaglobulinemia, CIPD, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, and Others
    • 4.4.2: APAC Intravenous Immunoglobulin Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.5: ROW Intravenous Immunoglobulin Market
    • 4.5.1: ROW Intravenous Immunoglobulin Market by Application: Hypogammaglobulinemia, CIPD, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, and Others
    • 4.5.2: ROW Intravenous Immunoglobulin Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Intravenous Immunoglobulin Market by Application
    • 6.1.2: Growth Opportunities for the Global Intravenous Immunoglobulin Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Intravenous Immunoglobulin Market by End Use
    • 6.1.4: Growth Opportunities for the Global Intravenous Immunoglobulin Market by Form
    • 6.1.5: Growth Opportunities for the Global Intravenous Immunoglobulin Market by Region
  • 6.2: Emerging Trends in the Global Intravenous Immunoglobulin Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Intravenous Immunoglobulin Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Intravenous Immunoglobulin Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Baxter
  • 7.2: Bayer
  • 7.3: Merck
  • 7.4: Biotest
  • 7.5: Top Bio
  • 7.6: CSL
  • 7.7: Octapharma
  • 7.8: Grifols
  • 7.9: Kedrion
  • 7.10: Takeda Pharmaceuical